IP Library › Granted Patent US 8,183,284
Granted Patent B2
US 8,183,284 · App. 11/489,756 · Granted May 22, 2012

Compositions for reducing the incidence of drug induced arrhythmia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,284
App. No.
11/489,756
Granted
May 22, 2012
Kind
B2
Abstract

In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.

Claims (23)

1. A method for reducing the incidence of azimilide-induced torsades de pointes consisting essentially of administering azimilide and aspirin to a patient having cardiac arrhythmia.

2. The method of claim 1 , wherein the azimilide is administered daily in amounts from about 75 mg to about 300 mg.

3. The method of claim 1 , wherein the aspirin is administered daily in amounts from about 80 mg to about 200 mg.

4. The method of claim 2 , wherein the azimilide is administered daily in an amount of about 75 mg.

5. The method of claim 2 , wherein the azimilide is administered daily in an amount of about 100 mg.

6. The method of claim 2 , wherein the azimilide is administered daily in an amount of about 125 mg.

7. A method for reducing the incidence of azimilide-induced torsades de pointes consisting essentially of administering azimilide and a statin to a patient having cardiac arrhythmia.

8. The method of claim 7 , wherein the azimilide is administered daily in amounts from about 75 mg to about 300 mg.

9. The method of claim 8 , wherein the azimilide is administered daily in an amount of about 75 mg.

10. The method of claim 8 , wherein the azimilide is administered daily in an amount of about 100 mg.

11. The method of claim 8 , wherein the azimilide is administered daily in an amount of about 125 mg.

12. A method for reducing the incidence of azimilide-induced torsades de pointes consisting essentially of administering azimilide, aspirin, and a statin to a patient having cardiac arrhythmia.

13. The method of claim 12 , wherein the azimilide is administered daily in amounts from about 75 mg to about 300 mg.

14. The method of claim 13 , wherein the azimilide is administered daily in an amount of about 75 mg.

15. The method of claim 13 , wherein the azimilide is administered daily in an amount of about 100 mg.

16. The method of claim 13 , wherein the azimilide is administered daily in an amount of about 125 mg.

17. The method of claim 12 , wherein the aspirin is administered daily in amounts from about 80 mg to about 200 mg.

18. The method of claim 1 , wherein the cardiac arrhythmia is atrial fibrillation.

19. The method of claim 7 , wherein the cardiac arrhythmia is atrial fibrillation.

20. The method of claim 12 , wherein the cardiac arrhythmia is atrial fibrillation.

21. The method of claim 1 , wherein the cardiac arrhythmia is ventricular arrhythmia.

22. The method of claim 7 , wherein the cardiac arrhythmia is ventricular arrhythmia.

23. The method of claim 12 , wherein the cardiac arrhythmia is ventricular arrhythmia.